Voyager Therapeutics (NASDAQ:VYGR) Downgraded by Wall Street Zen to Sell

Wall Street Zen downgraded shares of Voyager Therapeutics (NASDAQ:VYGR) from a hold rating to a sell rating in a research note released on Saturday morning.

A number of other equities research analysts also recently weighed in on the company. Truist Financial raised Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, March 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Voyager Therapeutics in a research report on Wednesday, April 15th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Voyager Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $16.50.

Voyager Therapeutics Trading Up 2.3%

VYGR opened at $4.05 on Friday. Voyager Therapeutics has a 12-month low of $2.64 and a 12-month high of $5.55. The business’s fifty day simple moving average is $4.04 and its 200-day simple moving average is $4.06. The company has a market capitalization of $244.70 million, a price-to-earnings ratio of -2.06 and a beta of 1.26.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07. Voyager Therapeutics had a negative return on equity of 53.03% and a negative net margin of 319.61%.The business had revenue of $1.19 million for the quarter, compared to the consensus estimate of $8.79 million. On average, equities research analysts predict that Voyager Therapeutics will post -1.73 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Alfred Sandrock sold 11,511 shares of the firm’s stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $3.87, for a total transaction of $44,547.57. Following the sale, the chief executive officer owned 472,549 shares of the company’s stock, valued at $1,828,764.63. This trade represents a 2.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 61,294 shares of company stock worth $233,241 over the last 90 days. 6.39% of the stock is owned by company insiders.

Institutional Investors Weigh In On Voyager Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Wexford Capital LP acquired a new stake in shares of Voyager Therapeutics during the third quarter worth about $42,000. ProShare Advisors LLC acquired a new stake in shares of Voyager Therapeutics during the fourth quarter worth about $44,000. CIBC Asset Management Inc acquired a new stake in shares of Voyager Therapeutics during the fourth quarter worth about $45,000. Coldstream Capital Management Inc. acquired a new stake in shares of Voyager Therapeutics during the third quarter worth about $55,000. Finally, EHP Funds Inc. acquired a new stake in shares of Voyager Therapeutics during the third quarter worth about $58,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.